Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: Long-term results of the TAX 324 randomised phase 3 trial

The Lancet Oncology

Volumn 12, Issue 2, 2011, Pages 153-159

  Lorch, Jochen H ^a   Goloubeva, Olga ^b   Haddad, Robert I ^a   Cullen, Kevin ^b   Sarlis, Nicholas ^c   Tishler, Roy ^a   Tan, Ming ^b   Fasciano, John ^a,d   Sammartino, Daniel E ^a   Posner, Marshall R ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

^d Morgan Stanley Smith Barney   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTINUOUS INFUSION; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NASOGASTRIC TUBE; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TRACHEOSTOMY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; FLUOROURACIL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 79151485327     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70279-5     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Horner M, Ries L, Krapcho M, et al. SEER cancer statistics review, 1975-2006, National Cancer Institute. Bethesda, MD, USA. Based on November 2008 SEER data submission, posted to the SEER web site (accessed August 1, 2010). http://seer.cancer.gov/csr/1975_2006/.
3. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21:92-98.
4. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004, 22:69-76.
5. Haddad RI, Shin DM Recent advances in head and neck cancer. N Engl J Med 2008, 359:1143-1154.
6. Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009, 101:142-152.
7. Forastiere A, Maor M, Weber R, et al. Long term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx-induction cisplatin/5FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc Am Soc Clin Oncol 2006, 24(suppl). abstr 5517.
8. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
9. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357:1705-1715. for the TAX 324 Study Group.
10. Domenge C, Hill C, Lefebvre JL, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 2000, 83:1594-1598.
11. Paccagnella A, Orlando A, Marchiori C, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994, 86:265-272.
12. Pignon JP, Bourhis J, Domenge C, Designé L Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000, 355:949-955. on behalf of the MACH-NC Collaborative Group.
13. Pignon JP, le Maitre A, Maillard E, Bourhis J Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
14. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357:1695-1704.
15. Calais G, Pointreau Y, Alfonsi M, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. Proc Am Soc Clin Oncol 2006, 24(suppl). abstr 5506.
16. Taylor SG, Murthy AK, Vannetzel JM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994, 12:385-395.
17. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989, 17:449-456.
18. Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995, 75:1343-1353.
19. Smith GL, Smith BD, Buchholz TA, et al. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 2008, 26:5119-5125.
20. Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 53:23-28.
21. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2009, 11:21-28.
22. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
23. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010, 28:4142-4148.